乙型肝炎病毒临床与基础研究中的未满足需求
慢性乙型肝炎已成为可治疗、可控制的疾病,核苷(酸)类似物(NUC)与聚乙二醇干扰素可延缓疾病进展并降低肝硬化、肝细胞癌(HCC)及死亡风险。但长期NUC治疗中的安全性与HCC风险分层监测、有限疗程NUC及NUC联合聚乙二醇干扰素的适用标准、e抗原阳性且肝功能正常病毒血症患者的管理、新生物标志物的整合等临床问题尚未解决;基础研究方面,高效细胞培养系统与动物模型、清除共价闭合环状DNA的治疗及免疫治疗等仍是实现功能性治愈和完全治愈的挑战。
要点
- NUC与聚乙二醇干扰素可延缓CHB进展并降低肝硬化、HCC及死亡风险
- 长期NUC治疗患者的安全性与HCC风险分层监测需求尚未满足
- 有限疗程NUC及NUC联合聚乙二醇干扰素的适用标准尚未确定
核心结论
- CHB已成为可治疗、可控制的疾病,但临床与基础研究仍存在多个未满足需求。
研究设计与样本
- 本文为简要综述,聚焦HBV临床与基础研究中的未满足需求。
主要发现
- NUC与聚乙二醇干扰素可有效延缓疾病进展并降低肝硬化、HCC及CHB相关死亡风险。
- 长期NUC治疗可实现病毒抑制且不良反应有限,但安全性与HCC风险分层监测仍待解决。
- 有限疗程NUC及NUC联合聚乙二醇干扰素的适用标准尚未确定。
- e抗原阳性且肝功能正常病毒血症患者的管理及新生物标志物的整合需进一步探索。
- 实现功能性治愈与完全治愈需在细胞培养系统、动物模型、清除cccDNA的治疗及免疫治疗方面取得突破。
临床怎么用
- 临床可应用NUC或聚乙二醇干扰素延缓CHB进展并降低肝硬化、HCC及死亡风险。
- 对长期NUC治疗患者需关注安全性及HCC风险分层监测。
- 有限疗程NUC及联合聚乙二醇干扰素的决策仍需进一步研究支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis B (CHB) has become a treatable and controllable disease. The current nucleos(t)ide analogue (NUC) and pegylated interferon therapies effectively help slow disease progression and reduce the risk of cirrhosis, hepatocellular carcinoma (HCC), and CHB-associated mortality. Long-term viral suppression is easily achievable by NUC therapy, with limited adverse reactions. However, several unmet requirements still exist, including safety and risk-stratified HCC surveillance among patients who received long-term NUC therapy. Criteria for determining which patients should receive finite-duration NUC therapy and which should receive combination therapy with both NUC and pegylated interferon remain unsettled. The management of hepatitis B virus (HBV) e antigen-positive viremic patients with normal liver function and the incorporation of new biomarkers to help manage CHB require further exploration. To achieve functional cure (ie, HBV surface antigen seroclearance) and complete cure (ie, eradication of covalently closed circular DNA) of CHB, several challenges in basic research must be addressed, including the development of an efficient cell culture system and animal models for HBV investigation, development of treatment to eradicate covalently closed circular HBV DNA, and development of immunotherapy for CHB. This brief review focuses on unmet needs in both clinical and basic HBV research.
引用
- Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis. 2017. PMID: 29156048. doi:10.1093/infdis/jix382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。